Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells

BACKGROUND: Standard therapy for acute promyelocytic leukaemia (APL) includes retinoic acid (all-trans retinoic acid (ATRA)), which promotes differentiation of promyelocytic blasts. Although co-administration of arsenic trioxide (ATO) with ATRA has emerged as an effective option to treat APL, the mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela, M, Glorieux, C, Stockis, J, Sid, B, Sandoval, J M, Felipe, K B, Kviecinski, M R, Verrax, J, Calderon, P Buc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150280/
https://www.ncbi.nlm.nih.gov/pubmed/25003661
http://dx.doi.org/10.1038/bjc.2014.380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150280/
https://www.ncbi.nlm.nih.gov/pubmed/25003661
http://dx.doi.org/10.1038/bjc.2014.380

Ejemplares similares